Related Experiment Video

Updated: May 18, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Host-targeting agents for prevention and treatment of chronic hepatitis C - perspectives and challenges

Mirjam B Zeisel1, Joachim Lupberger, Isabel Fofana

  • 1Inserm, U748, Strasbourg, France. Mirjam.Zeisel@unistra.fr

Journal of Hepatology
|October 9, 2012
PubMed

Insights

Host-targeting agents (HTAs) offer a promising new strategy against Hepatitis C virus (HCV) infection. These agents complement existing treatments by boosting immunity and have potential for broad application in difficult-to-treat patient groups.

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Hepatitis C virus (HCV) causes chronic liver disease and hepatocellular carcinoma, often necessitating liver transplantation.
  • Direct-acting antivirals (DAAs) have improved treatment but face challenges like drug resistance and limited efficacy in certain patient populations (e.g., immunocompromised, advanced liver disease, HIV/HCV co-infection).

Purpose of the Study:

  • To review host-targeting agents (HTAs) as a novel antiviral strategy against HCV.
  • To highlight HTAs in preclinical and clinical development for treating viral hepatitis.

Main Methods:

  • Literature review of host-targeting agents (HTAs) for Hepatitis C virus (HCV) infection.
  • Analysis of HTA characteristics, including resistance barriers, antiviral activity, and synergy with existing therapies.

Main Results:

  • HTAs present a high genetic barrier to resistance and exhibit pan-genotypic antiviral activity.
  • HTAs offer complementary mechanisms to DAAs, suggesting potential synergistic effects.
  • Several HTAs are currently in preclinical or clinical development for HCV treatment.

Conclusions:

  • HTAs represent a promising alternative or complementary approach to current antiviral therapies for HCV.
  • Their unique properties make them valuable for overcoming limitations of DAAs and treating complex patient cases.
  • Further development of HTAs could significantly advance HCV treatment strategies.

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...